Larimar Therapeutics (STU:ZA71) OCF Yield %: -34.81 (As of Jun. 25, 2026)


STU:ZA71 Larimar Therapeutics Inc STU:ZA71
34 GF Score
Price €3.18
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics OCF Yield %?

Larimar Therapeutics STU:ZA71 -0.62% 34 OCF Yield % is -34.81 as of Jun. 25, 2026. GuruFocus rates STU:ZA71 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,419 Biotechnology companies, Larimar Therapeutics ranks worse than 79.07% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Larimar Therapeutics's Trailing 12-Month Cash Flow from Operations is €-112.79 Mil, and Market Cap is €331.40 Mil. Therefore, Larimar Therapeutics's OCF Yield % for today is -34.81%.

The historical rank and industry rank for Larimar Therapeutics's OCF Yield % or its related term are showing as below:

STU:ZA71' s OCF Yield % Range Over the Past 10 Years
Min: -34.81   Med: 0   Max: -34.81
Current: -34.81


During the past 7 years, the highest OCF Yield % of Larimar Therapeutics was -34.81%. The lowest was -34.81%. And the median was %.

STU:ZA71's OCF Yield % is ranked worse than
79.07% of 1419 companies
in the Biotechnology industry
Industry Median: -8.46 vs STU:ZA71: -34.81

Larimar Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Larimar Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Larimar Therapeutics OCF Yield % Related Terms


Larimar Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Larimar Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Larimar Therapeutics OCF Yield % Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial -23.12 -16.26 -17.13 -28.47 -35.04

Larimar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -79.46 -43.38 -42.40 -47.71 -38.70

STU:ZA71 vs GLSI, RGNX, PBYI: OCF Yield % Comparison

For the Biotechnology subindustry, Larimar Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Larimar Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's OCF Yield % falls into.


STU:ZA71
34GF Score
Larimar Therapeutics Inc STU:ZA71
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Larimar Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Larimar Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-96.674 / 275.8588
=-35.04%

Larimar Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-38.591 * 4 / 398.91072
=-38.70%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -34.81 mean?
Larimar Therapeutics (STU:ZA71) has a OCF Yield % of -34.81 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Larimar Therapeutics and its competitors. According to the industry distribution chart, Larimar Therapeutics ranks #1122 out of 1419 companies in the Biotechnology industry, placing it in the top 79.1%.
Is Larimar Therapeutics' OCF Yield % too high?
Larimar Therapeutics' current OCF Yield % is -34.81. Based on the distribution chart, Larimar Therapeutics ranks #1122 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Larimar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' OCF Yield % compare to GLSI and RGNX?
According to the Biotechnology industry distribution chart, Larimar Therapeutics ranks #1122 out of 1419 companies for OCF Yield %. This places Larimar Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Larimar Therapeutics and its competitors. Larimar Therapeutics's current OCF Yield % is -34.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (STU:ZA71) has a current OCF Yield % of -34.81. The current OCF Yield % is -34.81. Larimar Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Larimar Therapeutics (STU:ZA71), the current OCF Yield % is -34.81 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Larimar Therapeutics Business Description

Other Exchanges LRMR:USAZA71:Germany
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score

Get the complete analysis for STU:ZA71

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.18
Price